# US 11,896,583 B2 · Tinostamustine for use in treating ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,583 B2
- Document ID: US11896583B2
- Status: Granted
- Kind: B2
- Application number: 16/621,893
- Filed: 2018-06-13
- Published: 2020-08-20
- Granted: 2024-02-13
- Earliest claimed: 2017-06-13
- Assignees: Purdue Pharma L.P.
- Applicants: Euro-Celtique S.A.
- Inventors: Thomas Jorg Mehrling
- Web page: https://patentgrep.com/patent/US11896583B2

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.

## Claims

### Claim 1

A method of treating ovarian cancer in a patient in need thereof, comprising administering to said patient an effective amount of tinostamustine or a pharmaceutically acceptable salt thereof, and carboplatin;
wherein tinostamustine or pharmaceutically acceptable salt thereof is administered at a dosage level of from 60 to 150 mg/m2 body surface area of the patient; and,
wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof on days 1, 8 and 15 of a 28-day treatment cycle.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ovarian cancer is from the omentum.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cancer is platinum resistant.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cancer is BRCA-1/2 wild type.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cancer is relapsed ovarian cancer, or a refractory ovarian cancer, or a combination thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cancer is a primary cancer.

### Claim 7 (depends on 1)

The method according to claim 1, wherein tinostamustine or pharmaceutically acceptable salt thereof is administered in combination with carboplatin and a further agent.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the further agent comprises paclitaxel.

### Claim 9 (depends on 1)

The method according to claim 1, wherein tinostamustine and carboplatin are administered concurrently, sequentially or separately.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof over an infusion time of 60 minutes, 45 minutes, or 30 minutes.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof at a dosage level of from 80 mg/m2 to 100 mg/m2 body surface area of the patient, on days 1 and 15 of a 28-day treatment cycle, over an infusion time of 60 minutes.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the patient is further treated with radiotherapy.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said radiotherapy is given to the patient in need thereof at a dose of 1 to 5 Gy over 5-10 consecutive days.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered over an infusion time of 45 minutes.